Loading clinical trials...
Loading clinical trials...
The TRANQUILITY 2 Trial: Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease
Conditions
Interventions
Reproxalap Ophthalmic Solution (0.25%)
Vehicle Ophthalmic Solution
Locations
1
United States
Andover Eye Associates (Raynham)
Raynham, Massachusetts, United States
Start Date
August 28, 2021
Primary Completion Date
March 4, 2022
Completion Date
March 4, 2022
Last Updated
March 18, 2025
NCT07463950
NCT07363824
NCT07396441
NCT07298811
NCT07295691
NCT07191847
Lead Sponsor
Aldeyra Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions